The dendritic cell and human cancer vaccines

Current Opinion in Immunology

Volumn 12, Issue 5, 2000, Pages 583-588

  Dallal, Ramsey M ^a   Lotze, Michael T ^a  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CARCINOEMBRYONIC ANTIGEN; CD14 ANTIGEN; CD32 ANTIGEN; CD34 ANTIGEN; CD64 ANTIGEN; CHEMOKINE RECEPTOR; CYTOKINE; DNA; GLYCOPROTEIN GP 100; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MONOPHENOL MONOOXYGENASE; RNA; TUMOR ANTIGEN;

CLINICAL TRIAL; DENDRITIC CELL; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; REVIEW;

EID: 0033818096     PISSN: 09527915     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0952-7915(00)00146-1     Document Type: Review

References (58)

1. Origin, maturation and antigen presenting function of dendritic cells
2. Dendritic cells: A link between innate and adaptive immunity
3. Dendritic cells use macropinocytosis and the mannose receptor to concentrate macro-molecules in the major histocompatibility complex class II compartment: Downregulation by cytokines and bacterial products
4. Type I (CD64) and type II (CD32) Fc gamma receptor-mediated phagocytosis by human blood dendritic cells
5. Characterization of expression, cytokine regulation, and effector function of the high affinity IgG receptor Fc gamma RI (CD64) expressed on human blood dendritic cells
6. Capture and processing of exogenous antigens for presentation on MHC molecules
7. Consequences of cell death: Exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells
8. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs
9. A monocyte conditioned medium is more effective than defined cytokines in mediating the terminal maturation of human dendritic cells
10. Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function
11. The actin-bundling protein fascin is involved in the formation of dendritic processes in maturing epidermal Langerhans cells
12. + blood dendritic cells
13. Induction of melanoma antigen-specific cytotoxic T lymphocytes in vitro by stimulation with B7-expressing human melanoma cell lines
14. Immunotherapy of cancer. Generation of CEA specific CTL using CEA peptide pulsed dendritic cells
15. A nonapeptide encoded by human gene MAGE-1 is recognized on HLA-A1 by cytolytic T lymphocytes directed against tumor antigen MZ2-E
16. Identification of the immunodominant peptides of MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes
17. Melanocyte lineage-specific antigen gp100 is recognized by melanoma derived tumor infiltrating lymphocytes
18. Autologous dendritic cells pulsed with MART-1, gp100, or tyrosinase peptides elicit anti-melanoma CTL from both normal donor and cancer patient peripheral blood lymphocytes in vitro
19. Peptide-pulsed dendritic cells induce antigen specific CTL-mediated protective tumor immunity
20. Rapid extracellular degradation of synthetic class I peptides by human dendritic cells
21. Generation of antimelanoma cytotoxic T lymphocytes from healthy donors after presentation of melanoma-associated antigen-derived epitopes by dendritic cells in vitro
22. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues
23. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors
24. Use of cellular and cytokine adjuvants in the immunotherapy of cancer
25. Immunotherapy: Fusion induces tumour rejection
26. Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: Enhancement by co-transfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-α
27. IL-12-engineered dendritic cells serve as effective tumor vaccine adjuvants in vivo
28. Effective tumor immunotherapy using bone marrow-derived dendritic cells (DC)'s genetically engineered to express interleukin 12
29. Enhancement of immune response to naked DNA vaccine by immunization with transfected dendritic cells
30. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo
31. Induction of tumor immunity and cytotoxic T lymphocytes responses using dendritic cells transfected with messenger RNA amplified from tumor cells
32. DNA-based immunization by in vivo transfection of dendritic cells
33. Interferon-α gene therapy for cancer: Retroviral transduction of fibroblasts and particle-mediated transfection of tumor cells are equally effective strategies for gene delivery in murine tumor models
34. Cytokine Gene Therapy
35. + cord blood cells under serum-free conditions
36. Dendritic cells transduced with an adenoviral vector encoding a model tumor-associated antigen for tumor vaccination
37. Dendritic cells infected with poxviruses encoding MART-1/Melan A sensitize T lymphocytes in vitro
38. Eradication of established murine tumors using a novel cell-free vaccine: Dendritic cell-derived exosomes
39. Dendritic cells generated from blood precursors of chronic myelogenous leukemia patients carry the Philadelphia translocation and can induce a CML-specific primary cytotoxic T-cell response
40. Human acute myeloblastic leukemia cells differentiate in vitro into mature dendritic cells and induce the differentiation of cytotoxic T cells against autologous leukemias
41. Cytokine upregulation of the antigen presenting function of acute myeloid leukemia cells
42. Immunotherapy with dendritic cells directed against tumor antigens shared with normal host cells results in severe autoimmune disease
43. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids
44. Phase I clinical trial: T-cell therapy for prostate cancer using autologous dendritic cells pulsed with HLA-A2*0201-specific peptides from prostate-specific membrane antigen
45. Evaluation of phase I/II clinical trials in prostate cancer with dendritic cells
46. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells
47. Induction of antigen-specific cytolytic T cells in situ in human melanoma by immunization with synthetic peptide pulsed autologous antigen presenting cells
48. Report from the International Union Against Cancer Tumor Biology Committee
49. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells
50. Interleukin-2: Developing additional cytokine gene therapies using fibroblasts or dendritic cells to enhance tumor immunity
51. Biology of Flt3 ligand and receptor
52. Expression of the flt3 receptor and its ligand on hematopoietic cells
53. Induction of dendritic cells (DC) by Flt3 ligand (FL) promotes the generation of tumor-specific immune responses in vivo
54. Dramatic increases in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: Multiple dendritic cell subpopulations identified
55. IL-12 and FLT3 ligand differentially stimulate lymphoid and myeloid dendropoiesis in vivo
56. Flt3 ligand induces tumor regression and antitumor immune responses in vivo
57. Development pathways of dendritic cells in vivo: Distinct function, phenotype, and localization of dendritic cell subsets in FLT3 ligand-treated mice